

LAVOISIER GLUCOSE 30 %, solution for infusion

QUALITATIVE AND QUANTITATIVE COMPOSITION

GLUCOSE MONOHYDRATE 33 g
(corresponding quantity in anhydrous glucose 30 g)
Water for injectable preparationss.q 100 ml
in each 100 ml of solution for infusion

Osmolarity: 1665 mOsm/l
Caloric glucose intake: 1200 Kcal/l
pH ranging from 3.5 to 6.5

PHARMACEUTICAL FORM

Solution for infusion

THERAPEUTIC INDICATIONS

- Caloric glucose intake
- Prevention against intra and extra cellular dehydration
- Rehydration in case water loss is higher than sodium chloride and other osmoles loss.
- Prophylaxis and treatment of ketosis in denutritions, diarrhoeas or vomiting.
- Vehicle for therapeutic supplementation in immediate pre-operative, operative and post-operative periods

POSODOLOGY AND ADMINISTRATION

Parenteral route. Infusion by central venous route

Use a dispenser with electric pump if possible

- Perfuse slowly and regularly over 24 hours, using a central venous catheter with distal end located at the entry of the right auricle.
- Posology is dependent on patient's clinical state, weight, age, diet and possible supplemental treatments.
- Infusion rate should not exceed a volume corresponding to 0.5 gram of glucose per minute.

CONTRA-INDICATIONS

Fluid imbalance.

SPECIAL WARNINGS AND PRECAUTIONS FOR USE

WARNINGS

HYPERTONIC SOLUTION.

INFUSION RATE MUST BE SLOW AND REGULAR.

Solution osmolarity requires that injection be delivered by central venous route.

- Verify physical integrity of container
- Inspect for limpidity of the solution
- Cleanse vial stopper

PRECAUTIONS FOR USE

- Clinical evaluation and laboratory determinations should be performed including sodium balance, glycosuria and ketonemia, potassium, phosphoremia and glycemia.
- If needed, supplement parenteral nutrition of insulin and potassium.
- In diabetics, glycemia and glycosuria should be monitored and insulin posology be adjusted if need be.
- Do not administer blood concomitantly using the same intravenous set because of the potential for pseudo-agglutination.

INTERACTIONS WITH OTHER DRUGS AND OTHER FORMS OF INTERACTIONS

Prior to any drug admixture, check for compatibility with the solution and container.

ADVERSE REACTION

- Hyperglycemia
- Polyuria from glucose
- Hyperosmolarity
- Dehydration
- Deep venous thrombosis

CLINICAL PHARMACOLOGY

Pharmacodynamics and pharmacokinetics

GLUCOSE SUPPLEMENT PRODUCT (B: hematopoietic stem cells blood and lymphoid organs).
Hypertonic solution of glucose.

Each liter solution provides 1 200 Kcal.

Metabolism is similar to glucose.

PHARMACEUTICAL DATA

Incompatibilities

- Inspect for possible discoloration and/or formation of precipitate, insoluble complex or crystals.
- Prior to any drug admixture, check whether its pH space efficacy matches that of glucose 30 % solution.
- When a drug is added to this solution, admixture should be dispensed immediately.

Shelf life: 5 years

Nature and contents of container

250 ml, 500 ml or 1000 ml bottles, colorless glass (type II), closed with a chlorobutyl stopper.

PACKAGING AND PRODUCT LICENSE NUMBER

Pharmacy Packaging:

Bottles (glass)

MA 305 851-4: 250 ml - 1 unit pack - Reimbursed by French Health Care Security 65 % -
Public Price including VAT: 2,69 €

MA 305 854-3: 500 ml - 1 unit pack - Reimbursed by French Health Care Security. 65 % -
Public Price including VAT: 3,24 €

Hospital Packaging:

Bottles (glass)

MA 553 505-9: 250 ml - 12 units pack - Approved for institutions.

MA 553 504-2: 500 ml - 12 units pack - Approved for institutions.

MA 553 503-6: 1000 ml - 6 units pack - Approved for institutions.

HOW SUPPLIED

Not applicable.

DATE OF REVISION

August 2005

CDM LAVOISIER

Laboratoires Chaix et Du Marais - 7, rue Labie - 75017 PARIS - FRANCE

Tel: +33 1 55 37 83 83

E-mail: contact@lavoisier.com

Fax: +33 1 55 37 83 84